53597-27-6 Usage
Originator
Alnovin,Hoechst
Uses
Anti-inflammatory.
Manufacturing Process
To a stirred refluxing solution of 20.2 g (0.1 mole) of 1-(1-pyrrolidino)-3,4-
dihydronaphthalene and 50 ml of toluene was added dropwise during 30 minutes under nitrogen a solution of 20.1 g (0.1 mole) of phenacyl bromide in
65 ml of dry toluene. The mixture was heated under reflux for 6 hours, diluted
with 50 ml of water, refluxed for 4 hours, and cooled. The layers were
separated and the aqueous phase was extracted with benzene. The organic
solution was dried over sodium sulfate and concentrated to a semi-solid.
Trituration with cold 30°-60° petroleum ether gave 23.6 g (78%) of solid, 2-
phenacyl-1-tetralone, MP: 73°-76°C. Recrystallization from 60°-90° petroleum
ether raised the melting point to 87°-88°C.A mixture of 20.0 g (0.076 mole) of 2-phenacyl-1-tetralone, 11.6 g (0.076
mole) of 5-aminosalicyclic acid, and 70 ml of glacial acetic acid was heated
under reflux for 4 hours, cooled, diluted with 10 ml of water and filtered. The
filter cake was washed with water and dried to provide 15.5 g of solid, 5-(4,5-
dihydro-2-phenyl-3H-benz[e]indol-3-yl)-2-hydroxy-benzoic acid. MP: 215°-
218°C. Recristallization from benzene-cyclohexane gave 6.5 g (22%) of yellow
crystals, MP: 245°-247°C.
Brand name
Alnovin(Hoechst-Roussel).
Check Digit Verification of cas no
The CAS Registry Mumber 53597-27-6 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,3,5,9 and 7 respectively; the second part has 2 digits, 2 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 53597-27:
(7*5)+(6*3)+(5*5)+(4*9)+(3*7)+(2*2)+(1*7)=146
146 % 10 = 6
So 53597-27-6 is a valid CAS Registry Number.
InChI:InChI=1/C25H19NO3/c27-24-13-11-18(14-21(24)25(28)29)26-22-12-10-16-6-4-5-9-19(16)20(22)15-23(26)17-7-2-1-3-8-17/h1-9,11,13-15,27H,10,12H2,(H,28,29)
53597-27-6Relevant articles and documents
COMPOUNDS FOR DISEASES AND DISORDERS
-
Page/Page column 136-137, (2008/06/13)
The invention provides novel compounds useful for the treatment of disorders associated with a defect in vesicular transport (e.g., axonal transport). The compounds have a substituents chosen from -L-C(=O)OH, -L-CH=CHC(=O)OH, -L-C(=O)NH2, -L-C(=O)NH(C1-3 alkyl), -L-C(=O)N(C1-3 alkyl)2, -L-S(=O)2(C1-3alkyl), -L-S(=O)2NH2, -L-S(=O)2N(C1-3 alkyl)2, -L-S(=O)2NH(C1-3 alkyl), -L-C(=O)NHOH, -L-C(=O)CH2NH2, -L-C(=O)CH2OH, -L-C(=O)CH2SH, -L-C(=O)NHCN, -L-NHC(=O)ORo, -L-C(=O)NHRo, -L-NH(C=O)NHRo, -L-C(=O)N(Ro)2, -L-NH(C=O)N(Ro)2, -L-sulfo, -L-(2,6 difluorophenol), -L-phosphono, and -L-tetrazolyl, where L is a linker.
Method of preparation of 3-(3-carboxy-4-hydroxyphenyl)-4,5-dihydro-2-phenylbenz (e) indole and valuable intermediates related thereto
-
, (2008/06/13)
A novel method of preparing the valuable compound 3-(3-carboxy-4-hydroxyphenyl)-4,5-dihydro-2-phenylbenz[e]indole is described, said compound possessing antiinflammatory and analgetic activity. Also described are novel intermediates useful in the disclose
